{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:44:13Z","timestamp":1760935453437,"version":"build-2065373602"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400131"],"award-info":[{"award-number":["82400131"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M752262"],"award-info":[{"award-number":["2024M752262"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cavitation is a special radiological feature of lung cancer, commonly observed in squamous cell lung cancer (SqCLC). This study intended to report two cases of cavitated and non-cavitated SqCLCs treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and discuss their different therapeutic responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>Two SqCLC patients with EGFR exon 19 deletions were treated with osimertinib as first-line therapy. One patient presented with a thick-walled cavitated lesion, while the other had a non-cavitated mass. After 3 months of osimertinib treatment, the cavitated SqCLC case showed disease progression. This patient subsequently underwent surgical resection of the primary tumor, followed by chemotherapy and immunotherapy, achieving an overall survival of 41 months to date. In contrast, the non-cavitated SqCLC case responded better to osimertinib, achieving partial remission with a progression-free survival of 14 months. Upon subsequent growth in both the primary lesion and lymph nodes, this patient began treatment with chemotherapy combined with immunotherapy, with a current overall survival of 31 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These cases suggest that osimertinib may be less effective as a first-line treatment for EGFR driver gene positive cavitated SqCLC than non-cavitated cases. Further research is needed to evaluate whether combining EGFR-TKIs with other therapies provides greater benefits than EGFR-TKIs alone for EGFR-positive cavitated SqCLC.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1626665","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:13:57Z","timestamp":1760933637000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Different therapeutic responses to osimertinib as first-line treatment for cavitated and non-cavitated squamous cell lung cancer with rare EGFR exon 19 deletion: two case reports and a literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Jing","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang Xiao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongzhao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2017.08.004","article-title":"Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer","volume":"112","author":"Tomizawa","year":"2017","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001025","article-title":"Architectural patterns are a relevant morphologic grading system for clear cell renal cell carcinoma prognosis assessment: comparisons with WHO\/ISUP grade and integrated staging systems","volume":"42","author":"Verine","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02543","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"41","author":"Johnson","year":"2023","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2371041650","article-title":"Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome","volume":"237","author":"Onn","year":"2005","journal-title":"Radiology"},{"key":"B5","first-page":"66","article-title":"Cavitated tumor as a clinical subentity in squamous cell lung cancer patients","volume":"50","author":"Kolodziejski","year":"2003","journal-title":"Neoplasma"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.02.013","article-title":"Cavitating squamous cell lung carcinoma-distinct entity or not? Analysis of radiologic, histologic, and clinical features","volume":"45","author":"Pentheroudakis","year":"2004","journal-title":"Lung Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2012.0027","article-title":"Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab","volume":"12","author":"Nishino","year":"2012","journal-title":"Cancer Imaging"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30475-7","article-title":"Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol","volume":"21","author":"Redman","year":"2020","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182582912","article-title":"Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes","volume":"7","author":"Phernambucq","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.11.111","article-title":"Current and emergent therapy options for advanced squamous cell lung cancer","volume":"13","author":"Socinski","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-426","article-title":"Clinicopathological characteristics of solitary cavitary lung cancer: a case-control study","volume":"12","author":"Liu","year":"2020","journal-title":"J Thorac Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14807","article-title":"Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma","volume":"14","author":"Nishimura","year":"2023","journal-title":"Thorac Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13431","article-title":"Osimertinib for compound EGFR exon 19 deletion\/T790M mutated lung squamous cell carcinoma","volume":"11","author":"Peng","year":"2020","journal-title":"Thorac Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.11.012","article-title":"First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations","volume":"140","author":"Shoji","year":"2020","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15081","article-title":"Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review","volume":"14","author":"Maeda","year":"2023","journal-title":"Thorac Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-814","article-title":"EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study","volume":"10","author":"Gieszer","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2020.103.13","article-title":"Down-regulation of HOTAIR reverses the resistance of gefitinib in HCC827 cells by increasing the expression of PTEN","volume":"23","author":"Zhai","year":"2020","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i22.7772","article-title":"Prognostic role of multiple abnormal genes in non-small-cell lung cancer","volume":"10","author":"Yan","year":"2022","journal-title":"World J Clin Cases"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nature11404","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Peter","year":"2012","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.12.001","article-title":"PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer","volume":"11","author":"Sood","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107123","DOI":"10.1016\/j.phrs.2024.107123","article-title":"PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities","volume":"202","author":"Liu","year":"2024","journal-title":"Pharmacol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmr.2018.07.010","article-title":"Lung abscess: Diagnosis and management","volume":"36","author":"Feki","year":"2019","journal-title":"Rev Mal Respir"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1188772","article-title":"Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2015.11.009","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell lung cancer","volume":"17","author":"Xu","year":"2016","journal-title":"Clin Lung Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1626665\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:13:59Z","timestamp":1760933639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1626665\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1626665"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1626665","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"article-number":"1626665"}}